Activities Report June 2026 and Appendix 4C
Filed with ASX · · 21 pages · English
Summary by 6ix AI
Osteopore Ltd. has released its quarterly report for the second quarter of the year, detailing its financial performance and activities during this period. The company reported revenue for the quarter, which was slightly below expectations due to slow market uptake of certain products and ongoing distribution transitions. Osteopore has gained market access rights for its orthopaedic products in Malaysia and secured FDA approval for its devices in Hainan, China.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Osteopore
- OSX secures Hainan FDA approval for orthopaedic devices
- Activities Report March 2026 and Appendix 4C
- Further Drawdown of T2 of the Redeemable Convertible Notes
- Clarification - agreement for injectable regen bone filler
- OSX signs agreement for injectable regenerative bone filler
Later from Osteopore
- OSX strikes orthopaedic deal for 5 Middle East countries
- Activities Report September 2026 and Appendix 4C
Follow Osteopore into a list and get an email when it puts out news.
Follow Osteopore